5-Iminodaunorubicin-hydrochloride-DataSheet-生命科学试剂-MedChemExpressVIP

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemE5-IminodaunorubicinhydrochlorideCat.No.:HY-138645ACASNo.:67324-99-6分⼦式:C₂₇H₃₁ClN₂O₉分⼦量:563作⽤靶点:DNA/RNASynthesis作⽤通路:CellCycle/DNADamage储存⽅式:4°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性数据体外实验DMSO:230mg/mL(408.53mM;Needultrasonic)H2O:8.33mg/mL(14.80mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制备储备液1mM1.7762mL8.8810mL17.7620mL5mM0.3552mL1.7762mL3.5524mL10mM0.1776mL0.8881mL1.7762mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥5mg/mL(8.88mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemESolubility:≥5mg/mL(8.88mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性5-Iminodaunorubicinhydrochloride⼀种醌改性蒽环类药物，具有抗肿瘤活性。5-Iminodaunorubicinhydrochloride在癌细胞中可诱导DNA链断裂。体外研究InmouseleukemiaL1210cells,5-Iminodaunorubicinproducesprotein-concealedDNAstrandbreaks.Manyofthe5-iminodaunorubicinbreaksmayarisefromapposedsingle-strandbreaks(i.e.,double-strandbreaks)[2].体内研究Inrat,5-Iminodaunorubicin(5-ID;1-16mg/kg)treatmentproduceswideningoftheQRScomplex,increasedR-andS-wavevoltage,andprolongedtheQalphaTinterval.Andthequinoneredoxcyclingissuppressedin5-Iminodaunorubicin.5-Iminodaunorubicinshowslowercardiotoxic[1].REFERENCES[1].RAJensen,etal.Electrocardiographicandtransmembranepotentialeffectsof5-iminodaunorubicinintherat.CancerRes.1984Sep;44(9):4030-9.[2].LAZwelling,etal.CytotoxicityandDNAstrandbreaksby5-iminodaunorubicininmouseleukemiaL1210cells:comparisonwithadriamycinand4'-(9-acridinylamino)methanesulfon-m-anisidide.CancerRes.1982Jul;42(7):2687-91.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchus